EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study

Richard G. Langley, Alice B. Gottlieb, Mark Lebwohl, E. James Song, Diamant Thaçi, Akimichi Morita, Philip J. Mease, Iain B. McInnes, Laure Gossec, Yoshiya Tanaka, Barbara Ink, Alexander Marten und 4 weitere

SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s814

DOI: 10.25251/hwgx7622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Richard G. Langley und 15 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: In patients (pts) with psoriatic arthritis (PsA) in the BE BOLD study, bimekizumab (BKZ; IL-17A/F inhibitor) reported superiority for the joint-focused primary endpoint (≥50% improvement from baseline [BL] in American College of Rheumatology response criteria [ACR50]) compared with risankizumab (RZB; IL-23 inhibitor) at Week (Wk) 16 (49.1% vs 38.4%, p

Zitieren

APA

Langley, R. G., Gottlieb, A. B., Lebwohl, M., Song, E. J., Thaçi, D., Morita, A., Mease, P. J., McInnes, I. B., Gossec, L., Tanaka, Y., Ink, B., Marten, A., Coarse, J., Manente, M., Szilagyi, B., & Merola, J. F. (2026). Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study. SKIN The Journal of Cutaneous Medicine, 10(6), s814. https://doi.org/10.25251/hwgx7622

Vancouver

Langley RG, Gottlieb AB, Lebwohl M, Song EJ, Thaçi D, Morita A, et al. Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s814. doi:10.25251/hwgx7622

BibTeX
@article{Langley2026,
  author = {Langley, Richard G. and Gottlieb, Alice B. and Lebwohl, Mark and Song, E. James and Thaçi, Diamant and Morita, Akimichi and Mease, Philip J. and McInnes, Iain B. and Gossec, Laure and Tanaka, Yoshiya and Ink, Barbara and Marten, Alexander and Coarse, Jason and Manente, Myriam and Szilagyi, Balint and Merola, Joseph F.},
  title = {Bimekizumab efficacy & safety versus risankizumab to 24 weeks in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis: An exploratory analysis of the BE BOLD study},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {6},
  pages = {s814},
  doi = {10.25251/hwgx7622}
}
Kostenlos starten →